Downstream receptor signaling inactivation has proved its efficacy as demonstrated by the results of the SHARP trial evaluating sorafenib, a multikinase inhibitor targeting the VEGFR and PDGFR kinases as well as raf, in advanced HCC. The gene discussed is RAF1; the disease is hepatocellular carcinoma.